Protara Therapeutics, Inc.
TARA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $128,081 | $173,416 | $139,564 |
| - Cash | $12,551 | $31,496 | $91,461 | $162,798 |
| + Debt | $2,436 | $3,948 | $4,227 | $4,483 |
| Enterprise Value | – | $100,533 | $86,182 | -$18,751 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$88 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$11,668 | -$16,488 | -$14,041 | -$14,230 |
| % Margin | – | – | – | – |
| Net Income | -$13,258 | -$14,960 | -$11,914 | -$12,769 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.31 | -0.35 | -0.29 | -0.48 |
| % Growth | 11.4% | -20.7% | 39.6% | – |
| Operating Cash Flow | -$12,452 | -$12,250 | -$14,713 | -$9,308 |
| Capital Expenditures | -$4 | -$22 | -$44 | $0 |
| Free Cash Flow | -$12,456 | -$12,272 | -$14,757 | -$9,308 |